Immuno-Oncology | Specialty

Preparing for the Future

December 15th 2014

In attending the Society of Urologic Oncology's annual meeting in Bethesda in early December, I was struck by the number of presentations focusing sharply on the burgeoning fields of biomolecular markers and immunotherapy and their application to urologic oncology.

Dr. Nanda On Pembrolizumab Potential for TNBC

December 12th 2014

Rita Nanda, MD, assistant professor of medicine and associate director of the Breast Medical Oncology Program at the University of Chicago, discusses the potential of pembrolizumab (Keytruda) for the treatment of triple-negative breast cancer (TNBC). A recent small-scale trial showed treatment response for 18.5% of patients with PD-L1 positive TNBC.

Dr. Edith Perez on Immune Checkpoint Inhibition in TNBC

December 10th 2014

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the potential for immune checkpoint blockage as treatment for patients with advanced breast cancer.

Pembrolizumab Elicits Antitumor Responses in TNBC

December 10th 2014

The PD-1 inhibitor pembrolizumab has demonstrated promising clinical activity with an acceptable safety profile in heavily pretreated patients with recurrent metastatic triple-negative breast cancer.

CAR T-Cell Therapy Elicits High Response Rate in Pediatric ALL

December 7th 2014

The anti-CD19 chimeric antigen receptor-modified T-cell therapy CTL019 demonstrated an impressive 92% complete response rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

Pembrolizumab Elicits Responses in Classical Hodgkin Lymphoma

December 7th 2014

Treatment with the PD-1 inhibitor pembrolizumab generated responses in 66% of patients with heavily pretreated classical Hodgkin lymphoma.

Nivolumab Achieves Encouraging Responses in Refractory Classical Hodgkin Lymphoma

December 6th 2014

In a small phase I trial, most patients with classical Hodgkin lymphoma, having previously failed three or more therapies, responded to the immunotherapy nivolumab.

ASH 2014 Preview: Checkpoint Inhibition, CAR Modified T Cells, and Novel Therapies

December 1st 2014

The top research being presented at the 2014 American Society of Hematology Annual Meeting will focus on immunotherapies and novel agents, according to Marcel R.M. van den Brink, MD, PhD.

Dr. van den Brink Highlights Five Abstracts From ASH 2014

December 1st 2014

Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, provides an overview of five notable studies being presented at the 2014 American Society of Hematology (ASH) Meeting and Exposition.

Protein Predicts Response to New Immunotherapy Drug

November 26th 2014

The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found.

Pfizer, Merck KGaA Collaboration Accelerates PD-L1 Inhibitor Development

November 25th 2014

Pfizer and Merck KGaA have agreed to collaborate on the development of the PD-L1 inhibitor MSB0010718C as a potential treatment for multiple types of cancer.

Levy Provides Update on Squamous Cell Lung Cancer Treatments

November 22nd 2014

Recent advances with immune checkpoint inhibitors could improve outcomes for patients with squamous cell non-small cell lung cancer, a traditionally hard to treat histology.

Dr. Sweeney on the Future of Prostate Cancer Research

November 18th 2014

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the future of prostate cancer research.

Dr. Herbst Discusses the State of Immunotherapy in Lung Cancer

November 18th 2014

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses the state of immunotherapy in lung cancer.

Experts Discuss Immunotherapy's Potential in Neuro-Oncology

November 17th 2014

Immunotherapy's promise as well as its challenges as a treatment for patients with brain cancer was the focus of a plenary session held November 15 at the Society of Neuro-Oncology's (SNO) 2014 Annual Meeting in Miami Beach.

Nivolumab Extends Survival in Phase III Melanoma Study

November 17th 2014

Frontline treatment with nivolumab significantly extended OS and PFS compared with dacarbazine in patients with untreated BRAF wild-type advanced melanoma.

Pembrolizumab Improves PFS, ORR Versus Chemotherapy in Phase II Melanoma Study

November 16th 2014

The PD-1 inhibitor pembrolizumab significantly improved PFS by over 43% compared with chemotherapy as a treatment for patients with metastatic melanoma who were refractory to ipilimumab.

Rindopepimut Leads to Improved PFS in Compassionate Use Study

November 16th 2014

The vaccine rindopepimut appears to help PFS and OS in patients with epidermal growth factor receptor variant III mutation in glioblastoma-a patient group with traditionally poor outcomes.

Sipuleucel-T Maker Dendreon Files for Bankruptcy

November 10th 2014

Dendreon, the maker of the first FDA-approved immunotherapy for advanced prostate cancer, sipuleucel-T (Provenge), has filed for chapter 11 bankruptcy.

Immunotherapies Continue to Impress in NSCLC Trials With Several Forecast for Approval

November 10th 2014

Roy S. Herbst, MD, PhD, led some of the first trials of gefitinib, the EGFR inhibitor that helped introduce targeted therapies of this important mutation into the treatment landscape of non–small cell lung cancer.

NEXT PAGE
PREVIOUS PAGE